Core Viewpoint - East Asia Pharmaceutical (605177) reported that as of January 20, 2026, the number of shareholders reached 9,990 [1] Group 1 - The company is actively engaging with investors through interactive platforms [1] - The increase in shareholder count indicates growing interest in the company [1]

Core Viewpoint - East Asia Pharmaceutical (605177.SH) forecasts a net loss attributable to shareholders of 75 million to 90 million yuan for the fiscal year 2025 [1] Group 1: Financial Performance - The company anticipates a net loss of 75 million to 90 million yuan for 2025 [1] Group 2: Product Development - During the reporting period, the company has submitted a batch of applications for raw materials and formulations [1] - The company has obtained its first formulation approval for Levofloxacin tablets, marking a significant breakthrough in its integrated development strategy of raw materials and formulations [1] - This approval will enrich the company's product line, enhance its competitiveness, and contribute to sustainable and stable development [1] - The experience gained from this approval will be valuable for future formulation registration certificate applications [1]

Core Viewpoint - East Asia Pharmaceutical (605177.SH) forecasts a net loss attributable to shareholders of 75 million to 90 million yuan for the fiscal year 2025 [1] Group 1: Financial Performance - The company anticipates a net loss of 75 million to 90 million yuan for 2025 [1] Group 2: Product Development - During the reporting period, the company has applied for a batch of new approvals for raw materials and formulations [1] - The company has obtained its first formulation approval for Levofloxacin tablets, marking a significant breakthrough in its integrated development strategy of raw materials and formulations [1] - This approval will enrich the company's product line, enhance its competitiveness, and promote sustainable, stable, and healthy development [1] - The experience gained from this approval will be valuable for future formulation registration certificate applications [1]

Core Viewpoint - East Asia Pharmaceutical (605177.SH) expects a significant net loss for the fiscal year 2025, indicating potential challenges ahead for the company [1] Financial Projections - The company anticipates a net profit attributable to shareholders of between -90 million and -75 million yuan for the year 2025 [1] - The projected net profit, excluding non-recurring gains and losses, is expected to range from -102 million to -87 million yuan for the same period [1]

Financial Performance Expectations - The company expects a net profit attributable to shareholders for 2025 to be between -90 million and -75 million yuan[4]. - The expected net profit attributable to shareholders, excluding non-recurring gains and losses, is projected to be between -102 million and -87 million yuan[4]. - In the previous year, the net profit attributable to shareholders was -100.66 million yuan, with a total profit of -118.17 million yuan[7]. Revenue and Profit Decline Factors - The decline in revenue is attributed to factors such as domestic price reductions, industry policies, and increased market competition, leading to a decrease in gross profit of approximately 108 million yuan[8]. - Fixed asset depreciation and increased interest expenses from bank loans are expected to impact the company's performance by around 32 million yuan[8]. - The company plans to recognize an inventory impairment provision of approximately 35 million yuan due to expected declines in the net realizable value of certain inventories[8]. Strategic Direction and Management Confidence - The company is committed to an integrated strategy for active pharmaceutical ingredients and formulations to navigate the complex pharmaceutical environment[9]. - Management remains confident in the company's future development and aims to improve operational quality and product competitiveness[10]. Financial Reporting and Risks - The financial data provided is preliminary and has not yet been audited by a registered accountant[11]. - Investors are advised to pay attention to investment risks as the final financial data will be disclosed in the official 2025 annual report[12].

Group 1 - East Asia Pharmaceutical Co., Ltd. experienced a stock price increase of 5.15%, reaching 21.45 CNY per share, with a trading volume of 48.87 million CNY and a turnover rate of 2.09%, resulting in a total market capitalization of 2.461 billion CNY [1] - The company, established on February 6, 1998, and listed on November 25, 2020, specializes in the research, production, and sales of chemical raw materials and pharmaceutical intermediates [1] - The main revenue composition of East Asia Pharmaceutical includes: β-lactam antibiotics (44.84%), anticholinergic and synthetic antispasmodic drugs (23.92%), quinolone antibiotics (12.86%), antifungal drugs for skin use (8.87%), other products (5.05%), and additional (supplementary) products (4.46%) [1] Group 2 - Noan Fund's Noan Multi-Strategy Mixed A (320016) entered the top ten circulating shareholders of East Asia Pharmaceutical, holding 811,700 shares, which is 0.72% of the circulating shares, with an estimated floating profit of approximately 852,300 CNY [2] - The Noan Multi-Strategy Mixed A fund was established on August 9, 2011, with a latest scale of 1.855 billion CNY, achieving a year-to-date return of 8.15% and a one-year return of 79.8% [2] - The fund manager, Kong Xianzheng, has a tenure of 5 years and 57 days, with the fund's total asset size at 5.608 billion CNY, achieving a best return of 101.07% and a worst return of -16.74% during his tenure [3]

Core Viewpoint - Zhejiang Dongya Pharmaceutical Co., Ltd. anticipates a net profit loss for the fiscal year 2025, indicating a downturn in operational performance [2]. Group 1: Financial Performance - The company’s financial department has preliminarily estimated that the net profit attributable to shareholders will be negative for the year 2025 [2]. - The company is committed to adhering to the Shanghai Stock Exchange listing rules and will expedite its financial accounting processes to provide a timely earnings forecast for 2025 [2]. Group 2: Disclosure and Communication - The final financial data will be disclosed in the official 2025 annual report, which will be the authoritative source for the company's financial performance [2]. - The designated media for information disclosure includes Shanghai Securities Journal, Securities Times, and the Shanghai Stock Exchange website [2].

Group 1 - The core point of the article is that East Asia Pharmaceutical reported its shareholder count as of January 10, 2026, which stands at 10,349 households [2]

（文章来源：证券日报） 证券日报网讯 1月14日，东亚药业发布公告称，公司预计2025年度归属于上市公司股东的净利润为负 值，2025年度经营业绩将出现亏损。 ...

北京商报讯（记者 丁宁）1月14日晚间，东亚药业（605177）发布公告称，经公司财务部门初步测算， 预计公司2025年度归属净利润为负值，2025年度经营业绩将出现亏损。 东亚药业表示，公司将严格遵循 《上海证券交易所股票上市规则》 等相关规定，加快推进财务核算工 作，尽快披露2025年度业绩预告。最终财务数据以公司正式披露的《2025年年度报告》为准。 ...